Overview
Avenue Biosciences, a Finnish protein engineering company, has raised $5.7 million in a seed extension round co-led by Balnord and Tesi, with additional participation from Voima Ventures, Inventure, University of Helsinki, and Dimerent. The funding aims to enhance protein biogenesis efficiency in therapeutic protein production, addressing challenges in manufacturing complex proteins. The total funding since 2024 now stands at $8.7 million, leveraging research from the University of Helsinki.
Products
Loading...
Recent Deals
Investors: Balnord, Tesi, Voima Ventures, Inventure, University of Helsinki, Dimerent
Avenue Biosciences, a Finnish protein engineering company, has raised $5.7 million in a seed extension round co-led by Balnord and Tesi, with additional participation from Voima Ventures, Inventure, University of Helsinki, and Dimerent. The funding aims to enhance protein biogenesis efficiency in therapeutic protein production, addressing challenges in manufacturing complex proteins. The total funding since 2024 now stands at $8.7 million, leveraging research from the University of Helsinki.